Viral and liver disease biotech Aligos Therapeutics files for a $100 million IPO - (NASDAQ via NewsPoints Desk)

  • Aligos Therapeutics, a biotechnology firm developing oligonucleotide therapies for viral and liver diseases, filed with the US Securities and Exchange Commission to raise up to $100 million in an initial public offering, as reported in NASDAQ.

  • According to the news source, the company's lead focus is to develop a functional cure for chronic hepatitis B (Hep B).

  • Aligos' pipeline of Hep B candidates includes ALG-010133, an S-antigen transport-inhibiting oligonucleotide polymer (STOPS) molecule that is currently in a Phase I trial in New Zealand.

To read more NewsPoints articles, click here.